News

Boosting regenerative medicine
Enlarge image

FundingUKGermanySpainNetherlands

Boosting regenerative medicine

30.05.2012 - Regenerative medicine centres foster their translational approach. An international initiative formed in Germany, a new centre is opened in Scotland.

Edinburgh/Enschede/Seville/Berlin/Toronto – The Scottish Centre for Regenerative Medicine (SCRM) officially started operations on May 28. The SCRM will conduct cutting-edge stem cell research to find new therapies for Multiple Sclerosis, Parkinson’s disease, motor neuron disease and heart and liver disease. Up to 250 scientists will work at the centre, which is funded by the University of Edinburgh, the Medical Research Council, Scottish Enterprise and the British Heart Foundation with up to £54m. The SCRM will put an special emphasis on translational efforts, turning laboratory discoveries faster into treatments. An additional newly founded £24m bioincubator, named „Nine, Edinburgh Bioquarter“ offers lab and office space to start-up ventures and established biotech companies.

Just days before, the Regenerative Medicine Coalition constituted itself in Germany’s capital city Berlin. Six translational medicine centres from Europe and North America joined forces to push stem cell based medicine forward. The Berlin-Brandenburg Centre for Regenerative Therapies (BRCT, Berlin, Germany), the Centre for Commercialisation of Regenerative Medicine (Toronto, Canada), the MIRA Institute for Biomedical Technology and Technical Medicine (Enschede, The Netherlands), the Andalusian Molecular Biology and Regenerative Medicine Centre (Seville, Spain), the McGowan Institute of Regenerative Medicine (Pittsburgh, USA) and the Institute for Regenerative Medicine (Winston Salem, USA) are among the founding members. „We plan to jointly tackle projects in order to accelerate the development of therapies”, announced Frank Lauter from BRCT.

http://www.european-biotechnology-news.com/news/news/2012-02/boosting-regenerative-medicine.html

PoliticsSwitzerland

23.10.2014 Just one day before its planned initial listing, Swiss Molecular Partners has cancelled its IPO. The reason: "unfavourable market conditions".

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

BusinessIreland

10.10.2014 Actavis has announced plans to merge with American pharma company Durata - a move that will strengthen their infectious diseases portfolio.

RegulationEU

07.10.2014 In an unprecedented move, the European Medicines Agency has approved a system allowing the future analysis of clinical trial data.

FinanceNetherlandsEU

06.10.2014 Another fund from the Netherlands has raised €92m in its first close and will invest the money in companies developing innovative therapeutics, medical devices and diagnostics.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • VITA 344.32 EUR6.67%
  • MORPHOSYS74.44 EUR4.04%
  • STRATEC BIOMEDICAL39.84 EUR3.94%

FLOP

  • CYTOS0.16 CHF-5.88%
  • CO.DON2.75 EUR-3.17%
  • ADDEX3.30 CHF-2.94%

TOP

  • BIOFRONTERA2.90 EUR31.2%
  • VITA 344.32 EUR8.0%
  • BB BIOTECH157.70 EUR7.3%

FLOP

  • PAION2.24 EUR-30.0%
  • CYTOS0.16 CHF-27.3%
  • MAGFORCE5.90 EUR-17.5%

TOP

  • SANTHERA85.50 CHF2335.9%
  • CO.DON2.75 EUR192.6%
  • PAION2.24 EUR163.5%

FLOP

  • CYTOS0.16 CHF-95.8%
  • THERAMETRICS0.08 CHF-42.9%
  • 4SC0.97 EUR-42.6%

No liability assumed, Date: 23.10.2014